120 results on '"Philis-Tsimikas, Athena"'
Search Results
2. Outcomes of the Dulce Digital-COVID Aware (DD-CA) discharge texting platform for US/Mexico border Hispanic individuals with diabetes
3. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-Standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4
4. Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-Standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4
5. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial
6. Real-Time Continuous Glucose Monitoring in the Hospital: A Real-World Experience
7. Continuous glucose monitoring in insulin-experienced individuals with type 2 diabetes switched to once-weekly insulin icodec versus once-daily comparators in ONWARDS 2 and 4: post-hoc analysis
8. Higher Derived Time in Range With IDegLira Versus Insulin Glargine U100 in People With Type 2 Diabetes
9. Mi Puente (My Bridge) Care Transitions Program for Hispanic/Latino Adults with Multimorbidity: Results of a Randomized Controlled Trial
10. Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes
11. 806-P: Correlation of Derived Time in Range (dTIR) and Time in Range (TIR) in People with Type 2 Diabetes (T2D) Treated with IDegLira (IDL) , Degludec, or Liraglutide: A Post Hoc Analysis of the DUAL I Trial
12. 100-LB: Glycemic Control Using Recommended Settings in Youth and Adults with Type 1 Diabetes (T1D) —Minimed 780G System with the Calibration-Free Guardian 4 Sensor Results
13. 493-P: Medical Assistant Health Coaching for Type 2 Diabetes in Primary Care: A Pragmatic, Cluster-Randomized Controlled Trial
14. 1489-PUB: Know Diabetes by Heart Campaign and Project Dulce: A Culturally Tailored Mobile-Based Self-Management Program Supports High-Risk Populations with Diabetes to Manage Cardiovascular Disease Risk
15. 956-P: Integrating an Evidence-Based Diabetes Digital Texting Program (Dulce Digital) via an EMR Patient Portal in a Large Health System
16. 582-P: Process Evaluation of Dulce Digital–Me: An Adaptive mHealth Intervention for Underserved Hispanics with Diabetes
17. 568-P: Predictors of Engagement and Adherence in a Text Messaging Diabetes Intervention for Hispanics
18. A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings
19. Dulce Digital-Me: protocol for a randomized controlled trial of an adaptive mHealth intervention for underserved Hispanics with diabetes
20. Digital health tools to promote diabetes education and management of cardiovascular risk factors among under-resourced populations
21. Higher derived time in range with insulin degludec/insulin aspart vs insulin glargine U100 in Japanese adults with T2D
22. Process evaluation of a medical assistant health coaching intervention for type 2 diabetes in diverse primary care settings
23. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
24. Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial
25. The Effect of Discontinuing Continuous Glucose Monitoring in Adults with Type 2 Diabetes Treated with Basal Insulin
26. The Effect of Discontinuing Continuous Glucose Monitoring in Adults with Type 2 Diabetes Treated with Basal Insulin
27. 100 years on: the impact of the discovery of insulin on clinical outcomes
28. 606-P: Higher Derived Time-in-Range with IDegLira vs. Insulin Glargine U100 in Patients with T2D
29. 1275-PUB: Call to Action: COVID-19 Pandemic Prompts Subcutaneous Treatment Option for Diabetes Ketoacidosis (DKA) in Hospital
30. Medical assistant health coaching (“MAC”) for type 2 diabetes in diverse primary care settings: A pragmatic, cluster-randomized controlled trial protocol
31. Care Team Integration in Primary Care Improves One-Year Clinical and Financial Outcomes in Diabetes: A Case for Value-Based Care
32. Glucose as the 5th Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a non-ICU Hospital Setting
33. Glucose as the 5th Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a non-ICU Hospital Setting
34. Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting
35. 2180-PUB: Integration of Continuous Glucose Monitoring in Diabetes Self-Management Education for Type 2 Diabetes Improves Glycemic Control
36. 646-P: Dulce Digital-Me: An Adaptive M-Health Intervention for Underserved Hispanics with Diabetes
37. 97-LB: Safety and Glycemic Outcomes of the MiniMed Advanced Hybrid Closed-Loop (AHCL) System in Subjects with T1D
38. 202-OR: Basal Insulin Digital Titration App vs. Enhanced Paper Titration Tool: A Randomized Control Study
39. 1021-P: HbA1c Levels and Rates of Hypoglycemia with Insulin Degludec U200 and Insulin Glargine U300 Stratified by Renal Function Subgroups: Post Hoc Analysis from the CONCLUDE Trial
40. 644-P: Social Media Campaign Raises Awareness of Diabetes Risks and Programs in Hispanic Communities
41. 2175-PUB: Feasibility and Preliminary Effectiveness of Continuous Glucose Monitoring for Diabetes Prevention
42. 960-P: Characteristics of U.S. Patients with Type 2 Diabetes Prescribed GLP-1RA+SGLT2i in Combination during 2018
43. Does Diabetes Distress Influence Clinical Response to an mHealth Diabetes Self-Management Education and Support Intervention?
44. My Bridge (Mi Puente), a care transitions intervention for Hispanics/Latinos with multimorbidity and behavioral health concerns: protocol for a randomized controlled trial
45. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials
46. The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL
47. Innovative Solutions to Care for Individuals With Diabetes in Underserved Populations
48. Innovative Diabetes Interventions in the U.S. Hispanic Population
49. 92 - Efficacy of Semaglutide by Background Sodium-Glucose Cotransporter-2 Inhibitor: A Posthoc Analysis of SUSTAIN 9
50. 884-P: Mi Puente: A Care Transitions Intervention for At-Risk Hispanics with Multiple Cardiometabolic Conditions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.